How AI Changes the Drug Discovery Equation

In a new Signal 49 Research series exploring artificial intelligence in drug discovery, OBIO® President and CEO Dr. Maura Campbell joins five industry leaders sharing their perspectives.

Dr. Maura Campbell, President and CEO of OBIO®, participated in this spotlight exploring the emerging role of artificial intelligence in drug discovery and examining Canada’s position within this rapidly evolving field. Interviewees consistently described public funding as important for supporting early-stage research and IP development. They highlight that aligning big funding bets to address spending challenges, such as in healthcare, is one way to overcome challenges. But it would need a mindset shift.

“We get companies seed funded with like $1 or $2 million through friends and family and angel investors, and then we have to get them to a point where a VC will actually look at them, which is usually that $2-$10 million, and that’s our gap right now.”
— Dr. Maura Campbell, President and CEO of OBIO® in the interview for Signal49 Research
Previous
Previous

Vasomune Therapeutics Completes Enrollment of Phase 2a Study of Pegevongitide (AV-001) in Patients Hospitalized with Pneumonia/ARDS

Next
Next

OBIO’s inaugural Early Adopter Health Network (EAHN®) Innovation Showcase